More Women With Breast Cancer Can Skip Risky Lymph Node Surgery, Landmark Trial Finds

May 31, 2026

CHICAGO — In a practice-changing development presented today at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, researchers revealed that many women with early-stage breast cancer can safely avoid an invasive, complications-prone armpit surgery. The phase 3 SENOMAC clinical trial—the largest randomized controlled trial of its kind—demonstrated that patients whose cancer has spread to only one or two “sentinel” lymph nodes do not experience worse survival rates when the remaining lymph nodes are left intact. By skipping this extensive procedure, known as completion axillary lymph node dissection (ALND), patients can avoid debilitating, lifelong side effects like lymphedema (chronic arm swelling) without compromising their cancer treatment.

The landmark findings are poised to immediately alter surgical protocols worldwide, reinforcing a long-term medical movement toward “de-escalation”—the practice of reducing invasive treatments when evidence shows they offer no therapeutic benefit.

Key Findings That Could Reshape Surgical Practice

The SENOMAC trial evaluated 2,766 patients across 67 sites in five countries between 2015 and 2021. All participants had early-stage, clinically node-negative (T1–T3) breast cancer but were found during surgery to have macrometastases—cancer deposits larger than 2 millimeters—in one or two of their sentinel lymph nodes.

Patients were randomly assigned to either undergo the traditional completion ALND or to omit the secondary surgery entirely. At the 5-year follow-up mark, the results revealed that removing the additional tissue provided no oncological advantage.

“The key finding is that more axillary surgery in itself does not improve survival in these patients,” the SENOMAC research team concluded, highlighting that the underlying biology of the tumor and systemic medical therapies play a far more critical role in survival than aggressive tissue removal.

Understanding the Stakes: What Is Axillary Dissection?

To understand why these findings are being hailed as a major victory for patient quality of life, it helps to look at the anatomy of breast cancer staging.

During an initial breast cancer operation, surgeons typically perform a sentinel lymph node biopsy (SLNB). As shown in the diagnostic diagram, this involves removing only the first few “guardian” nodes where cancer cells migrating from a tumor would realistically land first.

Historically, if those first few sentinel nodes tested positive for cancer, the standard response was a completion axillary lymph node dissection (ALND). This secondary procedure requires clearing out an additional 10 to 40 lymph nodes from deep within the armpit.

While effective for staging, stripping this lymphatic tissue disrupts fluid drainage and severs local nerves, exposing patients to severe, long-term complications:

• Lymphedema: A chronic, often painful swelling of the arm that affects 20% to 30% of ALND patients due to blocked lymphatic fluid.

• Nerve Damage: Persistent numbness, burning sensations, and chronic pain in the armpit and upper arm.

• Mobility Restraints: Permanent stiffness and limited range of motion in the shoulder joint.

“For many women, these complications persist for years and significantly impact daily activities, from lifting groceries to caring for children,” the trial investigators noted.

Building on Decades of Progress

The SENOMAC trial does not stand alone; rather, it represents the culmination of a multi-decade paradigm shift.

Earlier clinical trials paved the piece-by-piece foundation for this de-escalation strategy. The ACOSOG Z0011 trial (2017) first established that skipping ALND was safe for patients with limited sentinel node involvement, but that trial strictly looked at individuals receiving breast-conserving surgery (lumpectomies). Meanwhile, the AMAROS trial (2014) proved that targeted radiation could safely replace surgical dissection, and the IBCSG 23-01 trial cleared the omission of surgery for microscopic cancer deposits (micrometastases smaller than 2mm).

What makes SENOMAC groundbreaking is its vastly expanded criteria. It included populations previously deemed too risky to skip surgery and excluded from earlier data:

1. Mastectomy Patients: Individuals undergoing full breast removal, with or without reconstruction.

2. Larger Tumors: Patients with larger primary masses up to 5 centimeters (T3 tumors).

3. Extracapsular Extension: Patients whose cancer had begun to break through the outer walls of the lymph nodes themselves.

Expert Commentary: A Practice-Changing Moment

“This rigorous, large-scale trial proves that we can safely skip invasive axillary node dissection in patients with limited nodal disease,” said Dr. Jana de Boniface, lead investigator of the SENOMAC trial and a breast surgeon at the Karolinska University Hospital in Stockholm, Sweden. “By avoiding this additional surgery, we can drastically reduce long-term arm complications and improve arm function for breast cancer patients even years out from their diagnosis.”

Independent experts agree that the data will reshape clinical guidelines immediately. “Omission of axillary dissection is safe in properly selected patients,” noted surgical oncologist Dr. Kevin McGuire in an accompanying editorial context. However, he emphasized that this milestone is made possible because modern oncology relies on a holistic, multi-pronged approach rather than relying solely on the surgeon’s scalpel. Patients in the omission group still receive comprehensive, guideline-compliant backup treatments, including modern radiation therapy and systemic treatments like chemotherapy, hormone blockers, or HER2-targeted biological therapies.

Who Qualifies to Skip the Secondary Surgery?

According to the trial criteria and evolving oncological frameworks, a patient is generally considered a candidate to safely bypass completion lymph node dissection if they meet the following profile:

• Tumor Stage: T1, T2, or T3 classifications (tumors measuring up to 5cm in size).

• Nodal Status: Clinically node-negative prior to surgery (meaning no swollen nodes were felt by a doctor or seen on initial scans), with a final count of only 1 or 2 positive sentinel nodes.

• Surgical Scope: Undergoing either a lumpectomy or a mastectomy.

• Adjuvant Therapy Plan: The patient is fully cleared and willing to undergo subsequent recommended radiation and systemic medication therapies to clean up any microscopic cells left behind.

Important Limitations and Caveats

Despite the celebratory atmosphere at ASCO, medical authorities urge a tailored, cautious approach rather than a universal rule.

A recent 2025 meta-analysis raised a flag of caution for mastectomy patients, indicating that while skipping ALND is overwhelmingly safe for lumpectomy patients, certain historical tracking showed an association with better overall survival when ALND was kept for full mastectomies (OR = 0.75). Experts note this data may suffer from selection bias—where sicker patients were naturally given more aggressive surgeries—but it highlights the need for careful case-by-case discussion.

Furthermore, sub-analyses suggest that patients with advanced T3 or T4 tumors larger than 5cm still derive therapeutic benefit from full surgical removal. To clear up remaining gray areas, researchers have already launched SENOMAC-ULTRA, a follow-up trial designed to compare full dissection against an ultra-targeted removal of only clinically suspicious nodes.

What This Means for Patients

If you or a loved one is navigating an early-stage breast cancer diagnosis, this trial equips you with vital questions for your care team.

Actionable Steps for Patients:

• Ask About Eligibility: If a biopsy reveals cancer in 1 or 2 sentinel nodes, ask your surgical oncologist: “Am I eligible to omit a full axillary dissection based on the SENOMAC data?”

• Weigh Quality of Life: Consider that a microscopic 0.1% difference in regional recurrence risk may be an acceptable trade-off to completely bypass a 30% risk of permanent arm swelling and chronic pain.

• Seek a Second Opinion: If a surgical team recommends a traditional full axillary clearing, consider consulting a high-volume, multidisciplinary breast cancer center to ensure your treatment plan reflects the most current 2026 de-escalation standards.

“Each year, approximately half a million women around the world could avoid sentinel node biopsy or axillary dissection based on evolving evidence,” stated Dr. Oreste Gentilini, Director of the Breast Unit at the European Institute of Oncology in Milan. Dr. Gentilini is leading the ongoing SOUND trial, which is pushing boundaries even further by investigating whether certain low-risk patients can skip lymph node surgery entirely.

As breast cancer treatment transitions away from “maximal intervention” and toward precise, optimized care, the ultimate goal remains clear: curing the disease while leaving the patient whole.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.medscape.com/viewarticle/more-patients-breast-cancer-can-skip-axillary-dissection-2026a1000i1u